Cartesian partners with WestGene to advance in vivo CAR-T therapies for autoimmune diseases
Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to develop next-generation in vivo CAR-T treatments, combining WestGene's lipid nanoparticle platform with Cartesian's mRNA payload technology. A clinical trial is expected to begin in the se
View filing at SEC.gov →